HSDT - Helius Medical Technologies, Inc. Long-Term Liabilities to Capital

Brandmark of Helius Medical Technologies (HSDT)

The development of Helius Medical (HSDT) relies on the recognition of the PoNS system as a rehabilitation standard and the securing of insurance coverage. The dynamics of the long-term debt-to-equity ratio confirm these changes, with 0.00 becoming the new value for this metric. An eco-friendly approach to device energy efficiency, combined with the expansion of the neurological center network, contributes to strengthening the company's market position within the non-invasive neuromodulation segment.

HSDT - heliusmedical.com Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

HSDT (Helius Medical Technologies, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Share Price Helius Medical Technologies Inc.|HSDT - Analyst Consensus Forecast
- market capitalization data:
Market Value Helius Medical Technologies, Inc.|HSDT - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Helius Medical Technologies|HSDT - Company Book Value|Market Value to Book Value heliusmedical.com|HSDT - Aggregate Company Assets
- debt and liquidity data:
Debt to Capital Helius Medical|HSDT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Helius Medical Technologies Inc.|HSDT - Company Aggregate Debts|Debts to Book Value Helius Medical Technologies, Inc.|HSDT - Company Long-Term Debt|Company Short-Term Debt Helius Medical Technologies
Summary company analytics:heliusmedical.com
Core merchandise of Helius Medical

Helius Medical (HSDT) occupies a unique niche by developing neuromodulation devices for the treatment of multiple sclerosis. This indicator correlates liabilities with a maturity of over one year against the total equity. Investors utilize this balance to assess the funding sustainability of high-tech developments. A decline in share prices automatically increases risk by raising the debt load. The trend in the long-term debt-to-equity ratio reflects the issuer's current financial stability.

Analysis of competing companies

Long-Term Debt to Capital Ratio Biogen Inc|Neurocrine Biosciences Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital Regencell Corp RGC|Long-Term Debt to Equity Ratio AXSM (Axsome Therapeutics)|acadia-pharm.com - Long-Term Debt to Capital|Long-Term Debt to Equity Xenon (XENE)|VKTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity SUPN|Catalyst Corp (CPRX) - Long-Term Liabilities to Capital|DNLI - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient harmonybiosciences.com|Biohaven - Long-Term Debt to Capital|Long-Term Liabilities to Capital AMLX (Amylyx Pharmaceuticals Inc)|Long-Term Debt to Equity Trevi Pharma TRVI|Long-Term Debt to Equity Praxis Corp PRAX|Long-Term Debt to Capital AVXL (Anavex Life Sciences)|ceribell.com (CBLL) - Ratio of Long-Term Indebtedness to Capital|PRTA: Long-Term Debt to Equity Ratio|ALEC (Alector) - Long-Term Debt to Capital|ANNX: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Omeros Corp. (OMER)|Neurogene Inc. (NGNE) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ACIU (acimmune.com)|Voyager Therapeutics, Inc. - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Neumora NMRA|SCLX (Scilex Holding Co.) - Long-Term Debt to Capital|TVGN - Long-Term Liabilities to Capital|Long-Term Debt to Capital alphacognition.com|cogrx.com (CGTX) - Long-Term Debt to Capital Ratio|IKT: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Cassava Sciences Inc|Long-Term Debt to Capital ASRT (Assertio Holdings, Inc.)|Long-Term Debt to Equity Ratio coyatherapeutics.com (COYA)|Long-Term Debt to Capital VTGN (Vistagen)|Ovid Therapeutics Inc - Long-Term Debt to Capital|ABOS - Long-Term Debt to Equity|CRVO - Long-Term Debt to Equity|Long-Term Debt to Capital alteritytherapeutics.com ATHE|CLNN (Clene) - Long-Term Debt to Capital Coefficient|PEPG: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital jupiterneurosciences.com|Long-Term Debt to Capital Relmada Therapeutics, Inc. RLMD|Long-Term Debt to Capital Ratio Annovis Bio Inc ANVS|Long-Term Debt to Equity Ratio Grace Therapeutics (GRCE)|Firefly Neuro - Long-Term Loans to Capital Ratio|ANEW Medical, Inc. (KLTO) - Long-Term Debt to Equity|NRSN - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RVPH|Long-Term Liabilities to Capital MetaVia|NRXS (NeurAxis, Inc) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital PASG|Neuphoria Therapeutics Inc. (NEUP) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient NERV (minervaneurosciences.com)|ATHA: Long-Term Debt to Equity|Long-Term Liabilities to Capital Addex Therapeutics Ltd. ADXN|Long-Term Debt to Capital Alzamend (ALZN)|CYCN - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PTIX|KTTA (Pasithea Therapeutics Corp.) - Long-Term Liabilities to Capital|Long-Term Debt to Equity Cortigent Inc|Long-Term Debt to Equity Avenue Therapeutics Inc.|BCLI (Brainstorm Cell Therapeutics, Inc.) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Cara Therapeutics Inc CARA|Long-Term Debt to Equity Ratio CHRO (Chromocell Therapeutics)|Eliem Therapeutics, Inc. - Long-Term Debt to Capital|Long-Term Debt to Equity ITCI (Intra-Cellular)|Longboard Pharmaceuticals Inc (LBPH) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio Marinus MRNS|NKGN (NKGen Biotech Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity NRBO|Long-Term Debt to Equity Ratio sagerx.com|Synaptogenix - Long-Term Debt to Capital|Long-Term Liabilities to Capital Trevena Inc. (TRVN)|VIGL - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio Anew Medical Inc. WENA|Long-Term Debt to Capital CERE (Cerevel Therapeutics)